

**Ascendis Health Limited**  
(Incorporated in the Republic of South Africa)  
(Registration number 2008/005856/06)  
Share code: ASC  
ISIN: ZAE000185005  
("Ascendis" or "the group")




---

**POSTPONEMENT OF RELEASE OF ANNUAL RESULTS AND VOLUNTARY TRADING STATEMENT**

---

**Postponement of release of annual results**

Shareholders are advised that the group's annual results for the year ended 30 June 2018, which were scheduled to be released on 11 September 2018, will now be released on SENS on 25 September 2018.

The postponement is due to unexpected delays in finalising the annual results following the implementation of a new financial reporting system late in the financial year.

The board and management apologise for the inconvenience caused by the delay in the release of the results and the related investor presentations. The annual results and strategy presentations will now be held in Johannesburg on 25 September 2018 and in Cape Town on 26 September.

**Voluntary trading statement for the year ended 30 June 2018**

Ascendis shareholders are advised that the group's earnings for the year ended 30 June 2018 are anticipated to be within the following ranges:

<b>Continuing Operations</b>	<b>12 months ended 30 June 2018</b>	<b>12 months ended 30 June 2017 Reported</b>	<b>% increase</b>
Basic earnings per share	96.4 – 102.9 cents	85.9 cents	12% – 20%
Headline earnings per share	102.7 – 109.2 cents	90.8 cents	13% - 20%
Normalised headline earnings per share	157.8 – 164.3 cents	156.4 cents	1% – 5%

<b>Total Operations</b>	<b>12 months ended 30 June 2018</b>	<b>12 months ended 30 June 2017 Reported</b>	<b>% (decrease)/ increase</b>
Basic earnings per share	55.7 – 62.2 cents	68.7 cents	(19%) – (9%)
Headline earnings per share	74.5 – 81.0 cents	80.1 cents	(7%) - 1%
Normalised headline earnings per share	132.3 – 138.8 cents	145.7 cents	(9%) - (5%)

**Notes**

- As announced on SENS on 25 June 2018, the group has disposed of Ascendis Sports Nutrition South Africa and Ascendis Direct Selling and these businesses have been classified as discontinued operations.
- The results include the acquisition of Kyron Laboratories ("Kyron") with effect from 1 March 2018.

3. Normalised headline earnings per share from continuing operations comprise headline earnings per share from continuing operations adjusted for once-off costs of approximately R83 million (R177 million in the comparative period to June 2017) as well as amortisation costs. Shareholders are referred to the annual financial statements for the financial year ended 30 June 2017 for further information in respect of the normalisation adjustments.
4. Shareholders are reminded of the clarification provided by the Company on SENS on 1 February 2018 clarifying the amendment in its methodology in calculating normalised earnings per share. This change in methodology was not applied to the comparative normalised earnings per share figure presented above for the year ended 30 June 2017. Should the company have applied the revised methodology to the comparative figure, the normalised earnings per share from continuing operations for the year ended 30 June 2017 would have been 144.8 cents per share.

The financial information on which this trading statement is based has not been reviewed or reported on by the group's auditors.

7 September 2018  
Johannesburg

Sponsor



Questco Corporate Advisory (Pty) Ltd